Max Healthcare Q2 Revenue Rises 20% YoY to ₹3,219 Cr; PAT Up 10% to ₹448 Cr
Max Healthcare reported Q2 FY27 revenue of ₹3,219 Cr, up 20% YoY, and PAT of ₹448 Cr, up 10% YoY. Bed capacity increased to 5,518, with 77% occupancy. The company approved ₹415 Cr capex for new beds. Shareholding in Kalinga Hospital increased to 66.34%. Free cash from operations was ₹500 Cr.
The results show substantial revenue and profit growth, capacity expansion, and strategic increases in shareholding, all of which are material events for investors and indicate significant company development.
The company reported strong year-on-year growth in revenue and profit, along with significant investments in capacity expansion and strategic acquisitions, indicating positive business performance.
Max Healthcare Institute Limited announced its financial and operating results for the second quarter and half-year ended September 30, 2026. The company reported a network gross revenue of ₹3,219 Cr for Q2 FY27, a 20% year-on-year (YoY) increase and an 8% quarter-on-quarter (QoQ) growth. Network Profit After Tax (PAT) stood at ₹448 Cr, a 10% YoY growth and a 26% QoQ growth.
Key operational highlights for Q2 FY27 include a 20% YoY growth in Gross Revenue to ₹3,219 Cr and a 10% YoY growth in Network PAT to ₹448 Cr. Operational bed capacity increased by 16% YoY to 5,518 beds. Bed occupancy was at 77% for the quarter, with Occupied Bed Days (OBDs) up by 13% YoY. Over 31 lakh episodes of patient services were delivered, a 12% YoY growth. Free Cash from Operations was ₹500 Cr, with ₹292 Cr invested in expansion and ₹195 Cr disbursed as dividend.
Max Lab reported a gross revenue of ₹66 Cr, a 24% YoY growth, and Max@Home reported ₹86 Cr, a 37% YoY growth. International patient revenue grew 33% YoY to ₹307 Cr, accounting for approximately 10% of hospital revenue.
In terms of strategic developments, MSSH Dwarka commenced services at its new Oncology Block. The company's shareholding in Kalinga Hospital Limited (KHL) increased from approximately 58.28% to 66.34% following a rights issue. The Board also approved a capital expenditure of ₹415 Cr for adding 209 brownfield beds across existing hospitals.
For the half-year ended September 30, 2026, network gross revenue stood at ₹6,200 Cr, an 18% YoY growth, and network PAT was ₹805 Cr, a 7% YoY growth. Mr. Abhay Soi, Chairman and Managing Director, highlighted steady growth, expanding bed capacity, and strong demand for quality healthcare services.
What to do with a filing like this
Max Healthcare Institute Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Max Healthcare Institute Limited. Read the original for the full detail.